Strategic Diagnostics, Inc. (NASDAQ:SDIX)

High insider ownership. MicroCap just over 100m. 10m in cash on hand. Heating up. Good funds own. 1 analyst covers. 2007 may be pretty flat ... but 2008 may surge!(?)

Consolidation? NEOG competitor. A sector I think is quite interesting, but under the radar. Need more insight on management before making a RL commitment.

Background Sticky :

Strategic Diagnostics Secures Food Pathogen Testing Business from Three Major Food Processors
Tuesday January 23, 10:06 am ET
Estimated Annual Value Exceeds $800,000

NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq:SDIX - News) - today announced that it has sold its RapidChek® Listeria and RapidChek® SELECT(TM) for Salmonella test platforms to three major food processors with an estimated, combined annual value in excess of $800,000 per year. Product has started to ship in the current calendar quarter. As is common in the industry, no additional customer specifics are being released.
"Major food processors continue to embrace our methodologies as the preferred testing process to ensure the ongoing safety of their products and maintain consumer confidence," commented Matt Knight, President and CEO of Strategic Diagnostics. "Within this mature market, we continue to capture accounts with high-volume testing needs, demonstrating our ability to take market share from well established competitive methods and validating our technology. Our success is due to our ability to clearly demonstrate both the technical performance of our methods, and ultimately their superior cost in use."

With the introduction of RapidChek® SELECT(TM) for Salmonella in late August of 2006, SDI was, for the first time, able to offer state-of-the-art tests for the detection of all three regulated food pathogens in the U.S. In addition to the superior performance of each of the three methods, the Company also sees its ability to offer all three tests, on the same platform, as contributing to broader industry adoption going forward. The Company believes it is well-positioned to increase its market share within the Salmonella testing market, an industry currently estimated at $75 million annually.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.